Use of antidepressant serotoninergic medications and cardiac valvulopathy : a nested case-control study in the health improvement network (THIN) database
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society..
AIMS: To quantify the risk of cardiac valvulopathy (CV) associated with the use of antidepressant serotoninergic medications (SMs).
METHODS: We conducted a case-control study nested in a cohort of users of antidepressant SMs selected from The Health Improvement Network database. Patients who experienced a CV event during follow-up were cases. Cases were ascertained in a random sample of them. Up to 10 controls were matched to each case by sex, age, month and year of the study entry. Use of antidepressant SMs during follow-up was defined as current (the last prescription for antidepressant SMs occurred in the 2 months before the CV event), recent (in the 2-12 months before the CV event) and past (>12 months before the CV event). We fitted a conditional regression model to estimate the association between use of antidepressant SMs and the risk of CV by means of odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Sensitivity analyses were conducted to test the robustness of our results.
RESULTS: The study cohort included 752,945 subjects aged 18-89 years. Throughout follow-up, 1663 cases (incidence rate: 3.4 per 10,000 person-years) of CV were detected and were matched to 16,566 controls. The adjusted OR (95% CI) for current and recent users compared with past users of antidepressant SMs were 1.16 (0.96-1.40) and 1.06 (0.93-1.22), respectively. Consistent effect estimates were obtained when considering cumulative exposure to antidepressant SMs during follow-up.
CONCLUSIONS: These results would suggest that exposure to antidepressant SMs is not associated with an increased risk of CV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 74(2012), 3 vom: 22. Sept., Seite 536-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lapi, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidepressive Agents |
|---|
| Anmerkungen: |
Date Completed 04.01.2013 Date Revised 21.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/j.1365-2125.2012.04224.x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM215632745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215632745 | ||
| 003 | DE-627 | ||
| 005 | 20231224025911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2125.2012.04224.x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0718.xml |
| 035 | |a (DE-627)NLM215632745 | ||
| 035 | |a (NLM)22356433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lapi, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of antidepressant serotoninergic medications and cardiac valvulopathy |b a nested case-control study in the health improvement network (THIN) database |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2013 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. | ||
| 520 | |a AIMS: To quantify the risk of cardiac valvulopathy (CV) associated with the use of antidepressant serotoninergic medications (SMs) | ||
| 520 | |a METHODS: We conducted a case-control study nested in a cohort of users of antidepressant SMs selected from The Health Improvement Network database. Patients who experienced a CV event during follow-up were cases. Cases were ascertained in a random sample of them. Up to 10 controls were matched to each case by sex, age, month and year of the study entry. Use of antidepressant SMs during follow-up was defined as current (the last prescription for antidepressant SMs occurred in the 2 months before the CV event), recent (in the 2-12 months before the CV event) and past (>12 months before the CV event). We fitted a conditional regression model to estimate the association between use of antidepressant SMs and the risk of CV by means of odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Sensitivity analyses were conducted to test the robustness of our results | ||
| 520 | |a RESULTS: The study cohort included 752,945 subjects aged 18-89 years. Throughout follow-up, 1663 cases (incidence rate: 3.4 per 10,000 person-years) of CV were detected and were matched to 16,566 controls. The adjusted OR (95% CI) for current and recent users compared with past users of antidepressant SMs were 1.16 (0.96-1.40) and 1.06 (0.93-1.22), respectively. Consistent effect estimates were obtained when considering cumulative exposure to antidepressant SMs during follow-up | ||
| 520 | |a CONCLUSIONS: These results would suggest that exposure to antidepressant SMs is not associated with an increased risk of CV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT2B |2 NLM | |
| 700 | 1 | |a Nicotra, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Vannacci, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Pieri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Mugelli, Niccolò |e verfasserin |4 aut | |
| 700 | 1 | |a Zambon, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Corrao, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Mugelli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rubino, Annalisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 74(2012), 3 vom: 22. Sept., Seite 536-44 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2012 |g number:3 |g day:22 |g month:09 |g pages:536-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2125.2012.04224.x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2012 |e 3 |b 22 |c 09 |h 536-44 | ||